Scadenza: 8 March 2021
Scadenze successive:
Online submission with digital signature of the PI and Legal Representative March 22, 2021
Topic:
All proposed research plans must have a clear objective that is consistent with the AIRC mission and will likely lead to advances in cancer biology, prevention, monitoring, diagnosis, or treatment of tumors in the near term.
Research plans should fall into one of the following research areas:
• Angiogenesis • Cancer genetics • Cancer stem cells • Cell adhesion, migration, invasion and metastasis • Cell cycle control and cell division • Cell death and apoptosis • Chemotherapy • Computational biology • Control of gene expression and epigenetics • Diagnosis • DNA damage and repair • Epidemiology and prevention • Gene therapy • Hormone therapy • Imaging • Immunotherapy • Infection, inflammation and cancer • Metabolism • Prognosis • Radiobiology and radiotherapy • Resistance to therapy • Signal transduction and intracellular trafficking • Structural biology • Targeted therapy and new therapeutics • Tumor immunology • Tumor microenvironment.
Ente finanziatore:
Airc Foundation
Duration of the project: 5 years
Who can participate:
PIs can be of any nationality and are expected to have operated to the highest standards of integrity during their whole career.
Applicants must have at least one last- or co-last-author primary research paper, in press or published in the last 5 years.
Applicants must have a total active Impact Factor (IF) of at least 30 in the last 5 years.
Partnership: Not Mandatory
Status:
Closed
Quota finanziabile:
100%
Topic:
All proposed research plans must have a clear objective that is consistent with the AIRC mission and will likely lead to advances in cancer biology, prevention, monitoring, diagnosis, or treatment of tumors in the near term.
Research plans should fall into one of the following research areas:
• Angiogenesis • Cancer genetics • Cancer stem cells • Cell adhesion, migration, invasion and metastasis • Cell cycle control and cell division • Cell death and apoptosis • Chemotherapy • Computational biology • Control of gene expression and epigenetics • Diagnosis • DNA damage and repair • Epidemiology and prevention • Gene therapy • Hormone therapy • Imaging • Immunotherapy • Infection, inflammation and cancer • Metabolism • Prognosis • Radiobiology and radiotherapy • Resistance to therapy • Signal transduction and intracellular trafficking • Structural biology • Targeted therapy and new therapeutics • Tumor immunology • Tumor microenvironment.
Who can participate:
PIs can be of any nationality and are expected to have operated to the highest standards of integrity during their whole career.
Applicants must have at least one last- or co-last-author primary research paper, in press or published in the last 5 years.
Applicants must have a total active Impact Factor (IF) of at least 30 in the last 5 years.
Programme:
Consortium: Not required
Status: Open
Total budget:
Funding rate:
100%
